Combination of MIG (CXCL9) chemokine gene therapy with low-dose cisplatin improves therapeutic efficacy against murine carcinoma (Q45857995)

17 December 2017

title

Combination of MIG (CXCL9) chemokine gene therapy with low-dose cisplatin improves therapeutic efficacy against murine carcinoma (English)

1 reference

17 December 2017

0 references

Zhang R

1

1 reference

17 December 2017

Tian L

2

1 reference

17 December 2017

Chen LJ

3

1 reference

17 December 2017

Xiao F

4

1 reference

17 December 2017

Hou JM

5

1 reference

17 December 2017

Zhao X

6

1 reference

17 December 2017

Li G

7

1 reference

17 December 2017

Yao B

8

1 reference

17 December 2017

Wen YJ

9

1 reference

17 December 2017

Li J

10

1 reference

17 December 2017

Zhang L

11

1 reference

17 December 2017

Chen XC

12

1 reference

17 December 2017

Luo F

13

1 reference

17 December 2017

Peng F

14

1 reference

17 December 2017

Jiang Y

15

1 reference

17 December 2017

Wei YQ

16

1 reference

17 December 2017

publication date

4 May 2006

1 reference

17 December 2017

published in

Gene Therapy

1 reference

17 December 2017

volume

13

1 reference

17 December 2017

issue

17

1 reference

17 December 2017

page(s)

1263-1271

1 reference

17 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.gt.3302756

exact match

0 references

cites work

Metronomic scheduling: the future of chemotherapy?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302756

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302756

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302756

Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302756

Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302756

Development of angiogenesis inhibitors for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302756

Antiangiogenic gene therapy of cancer: recent developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302756

The biology of chemokines and their receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302756

The functional role of the ELR motif in CXC chemokine-mediated angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302756

Human Mig chemokine: biochemical and functional characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302756

The application of an anti-angiogenic gene (thrombospondin-1) in the treatment of human prostate cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302756

Inhibition of angiogenesis in vivo by interleukin 12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302756

Platelet factor 4: an inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302756

Retroviral gene transfer of interferon-inducible protein 10 inhibits growth of human melanoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302756

The CXC chemokine, monokine induced by interferon-gamma, inhibits non-small cell lung carcinoma tumor growth and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302756

The CC chemokine 6Ckine binds the CXC chemokine receptor CXCR3

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302756

Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302756

Combination of low-dose gemcitabine and recombinant quail vascular endothelial growth factor receptor-2 as a vaccine induces synergistic antitumor activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302756

Angiogenesis and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302756

Enhanced antitumor effect of the combination of tumstatin gene therapy and gemcitabine in murine models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302756

Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302756

A gene therapy for cancer based on the angiogenesis inhibitor, vasostatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302756

T cytotoxic-1 CD8+ T cells are effector cells against pneumocystis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302756

Combination of low-dose cisplatin and recombinant xenogeneic endoglin as a vaccine induces synergistic antitumor activities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302756

Quantitative assessment of angiogenesis and tumor vessel architecture by computer-assisted digital image analysis: effects of VEGF-toxin conjugate on tumor microvessel density

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302756

Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302756

Continuous low-dose anti-angiogenic/ metronomic chemotherapy: from the research laboratory into the oncology clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302756

7 January 2021

High-time chemotherapy or high time for low dose

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302756

7 January 2021

Anti-angiogenesis therapy and strategies for integrating it with adjuvant therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302756

7 January 2021

Angiogenesis. A boost for tumor starvation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302756

7 January 2021

A Role for the Interferon-Inducible Protein 10 in Inhibition of Angiogenesis by Interleukin-12

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302756

7 January 2021

Mig and IP-10: CXC chemokines that target lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302756

7 January 2021

Schedule-dependent pharmacodynamic effects of gemcitabine and cisplatin in mice bearing Lewis lung murine non-small cell lung tumours

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302756

7 January 2021

Inhibition of tumor growth with a vaccine based on xenogeneic homologous fibroblast growth factor receptor-1 in mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302756

7 January 2021

Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302756

7 January 2021

Immunogene therapy of tumors with vaccine based on xenogeneic epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302756

7 January 2021

Identifiers

DOI

10.1038/SJ.GT.3302756

1 reference

17 December 2017

Dimensions Publication ID

0 references

1 reference

17 December 2017